Abstract Previous studies document that PGE 2 and adenosine suppress production of inXammatory cytokines. The present study demonstrates for the Wrst time that (1) PGE 2 and 2-chloroadenosine (CADO; a stable analog of adenosine) directly inhibit the cytolytic function of human tumorinWltrating lymphocytes (TILs); (2) the combination PGE 2 and CADO have additive suppressive eVects; and (3) the cooperative immunosuppressive actions of PGE 2 and CADO are mediated via EP2 receptors (EP2Rs) and A 2A receptors (A 2A Rs) and are due to ampliWcation of cAMP production, activation of protein kinase A (PKA) and T cell receptor (TCR) inhibitor Csk leading to inhibition of Lck, ZAP-70 and Akt phosphorylation. (4) During ex vivo expansion, TILs undergo three stages of diVerentiation converting from TILs with high cytotoxic activity and relative resistance to combined EP2R/A 2A R suppression (stage I) to TILs retaining high cytotoxicity and gaining sensitivity to combined suppression (stage II) and then to TILS that are less cytotoxic and very sensitive to combined suppression (stage III). (5) Finally, we Wnd that pretreatment of TILs with non-inhibitory concentrations of EP2R agonists (such as PGE 2 or butaprost) or A 2A R agonists (such as CADO or CGS21680) increases their cytotoxic activity and induces resistance to EP2R and A 2A R inhibitory signaling (crossresistance) due to homologous and heterologous desensitization and internalization of EP2Rs and A 2A Rs, thus preventing their inhibitory signaling. We conclude that inducing resistance of TILs to the suppressive eVects of PGE 2 and adenosine in the tumor microenvironment could represent a novel strategy for improving the eYcacy of adoptive immunotherapy.
Introduction
Adoptive therapy with anti-melanoma-speciWc cytotoxic T lymphocytes (CTLs) induces clinical responses in 50-72% of patients with advanced melanoma [1, 2] . This success is achieved by depleting the host's lymphocytes with chemotherapy or irradiation prior to adoptive transfer of ex vivo expanded melanoma inWltrated CTLs. This procedure eliminates T regulatory cells and increases the availability of cytokines essential for the survival and function of transfused CTLs [1, 2] . Nonetheless, as transferred CTLs enter the tumor, various microenvironmental factors, such as TGF-, IL-10 and VEGF, inhibit CTL activity and compromise therapeutic eYcacy [3] [4] [5] [6] [7] .
Along these lines, emerging evidence suggests that tumor-derived adenosine and PGE 2 may also function as immunosuppressive molecules in the tumor microenvironment [8] [9] [10] [11] [12] [13] . PGE 2 and adenosine have much in common. They both exert various biological eVects by engaging receptors (Rs) that couple to signal transduction systems via G-proteins: EP1Rs, EP2Rs, EP3Rs and EP4Rs for PGE 2 ; and A 1 Rs, A 2A Rs, A 2B Rs and A 3 Rs for adenosine [11, 14] . Moreover, both PGE 2 and adenosine can stimulate adenylyl cylcase via EP2Rs/EP4Rs and A 2A Rs/A 2B Rs, respectively [11, 14] . In lymphoid cells, cAMP signaling mediates a potent immunosuppressive eVect and the magnitude of immunosuppression is a function of the amount of cAMP produced [12, 15, 16] . This information suggests that in combination PGE 2 and adenosine increase cAMP production and cause ampliWcation of signaling via the cAMP-PKA pathway, yielding a more potent immunosuppressive eVect than each modality acting separately [17] . This concept seems likely because intratumor inXammation and hypoxia cause over-production of both adenosine and PGE 2 [18] [19] [20] .
The above considerations may have clinical signiWcance. Adoptively transferred immune T cells upon tumor inWltration may be inactivated by the combined actions of adenosine and PGE 2 . However, direct experimental support of this possibility is lacking because knowledge regarding the immunosuppressive properties of adenosine and PGE 2 is based mostly on results obtained from experimental models of inXammation and autoimmunity. Although these studies demonstrate the ability of adenosine and PGE 2 to suppress inXammatory cytokine production by various immune cells [10, 12, 13, 21, 22] , only a few studies demonstrate that adenosine inhibits anti-tumor, T cell-mediated responses. Pharmacological or genetic blockade of cAMP-elevating, A 2A R signaling substantially improves the eYcacy of antitumor immune responses and inhibits growth of local and metastatic tumors in mice [20] . However, it remains unknown whether adenosine and PGE 2 are able to inhibit the cytotoxic activity of human antitumor-speciWc CTLs. Therefore, in the present study, we investigated the eVects of adenosine and PGE 2 on the cytotoxic activity of antimelanoma-speciWc CTLs used for adoptive therapy of patients with metastatic melanoma. Moreover, we investigated the mechanisms of the suppressive eVects of adenosine and PGE 2 and identiWed three transitional stages of tumor-inWltrating lymphocytes (TILs) diVerentiation during their in vitro expansion characterized by reduced cytolytic ability and increased sensitivity to the suppressive eVects of EP2R and A 2A R agonists.
Because of the importance of developing approaches to increase TIL cytotoxic activity by inducing resistance to immunosuppression mediated by tumor-produced adenosine and PGE 2 , we also examined the eVects of brief pretreatment of anti-melanoma-speciWc TILs during stages II and III with relatively non-inhibitory concentrations of EP2R and A 2A R agonists. Importantly, such treatments increased the cytotoxic activity of TILs, rendered them resistant to A 2A R and EP2R suppressive signaling and induced cross-resistance due to homologous and heterologous desensitization and internalization of EP2Rs and A 2A Rs.
Materials and methods

Reagents
2-Chloroadenosine (CADO), PGE 2 , rolipram, forskolin and butaprost were purchased from Sigma-Aldrich (St. Louis, MO, USA). CGS21680 (CGS) was from Tocris (Ellisville, MO, USA). IL-2 was provided by the BRB Preclinical Repository, NCI, NIH.
Tumor-inWltrating lymphocytes
Cryopreserved samples of TILs that were used for adoptive therapy of human metastatic melanomas were provided by Steven Rosenberg (Surgery Branch, NCI, NIH). TILs were propagated in RPMI 1640 medium supplemented with 10% fetal bovine serum, glutamine, nonessential aminoacids, 2-ME, antibiotics and IL-2 (5,000 IU/ml). In total, we tested the cytotoxic activity of nine individual HLA A2 + MART-1-speciWc TIL lines. Their sensitivity to suppressive eVects of PGE 2 and/or CADO was also analyzed.
Cytotoxic activity of TILs
The cytotoxic activity of TILs was tested against 51 Crlabeled T2 cells that were loaded with MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide (10 g/ml) in the presence of the tested agents. After 4 h of incubation, supernatants (25 l) were transferred into yttrium silicate scintillator-coated white microplates (LumaPlate™-96, PerkinElmer, Boston, MA, USA) and the level of -emission by released 51 Cr was measured in a -counter. The percentage of cytotoxicity was calculated as previously described [22] . In some experiments, HLA-A*0201 + /DRB1*0401 + UPCI-MEL-136 melanoma cells isolated from a primary human melanoma were used as targets (gift from Dr. Hassan Zarour, University of Pittsburgh).
Western blot analysis
Tumor-inWltrating lymphocytes were equilibrated for 1 day without IL-2 and then stimulated with plate bound anti-CD3 (5 g/ml) in the presence of CADO and PGE 2 for 30 min. TILs were lysed and protein extracts (50 g) were resolved using 10% SDS-PAGE and transferred to PVDF membranes. The membranes were incubated with the primary antibodies recognizing phosphorylated cAMP responding element-binding protein (CREB) (anti-phospho S129 + S133; 1:1,000, Abcam, England), total CREB (1:2,000, Abcam), phosphorylated Csk (anti-phospho S364 1:200, Abcam), total Csk (1:200, Santa Cruz), phosphorylated Lck (anti-phospho Tyr505, 1:1,000 or anti-phospho Tyr394, 1:1,000, Cell Signaling), phosphorylated Akt (antiphospho Ser473, 1:100, Cell Signaling), total Akt (1:500, Cell Signaling) and -actin (1:500, Santa Cruz). The horseradish peroxidase-labeled polyclonals were used as secondary antibodies (Santa Cruz). The signals were detected by ECL (Amersham). Films were scanned and analyzed by ImageQuanT data analysis software (Molecular Dynamics) [17] .
Flow cytometry
TILs #2009 were stimulated with anti-CD3 in the absence or presence of CADO (C; 50 M) and PGE 2 (P; 0.5 M) for 30 min. Unstimulated cells served as a control. Cells were Wxed, permeabilized and stained with rabbit antiphospho-Zap-70 (Tyr493) and then with the secondary anti-rabbit IgG-PE (Santa Cruz). Cell Xuorescent intensity was analyzed by Xow cytometry.
Real-time PCR
RNA was isolated from human TILs #2009 using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was produced from 500 ng to 1 g of RNA by using the RT2 First Strand kit (SABioscience, Frederick, MD, USA). Real-time PCR was carried out as described previously [17] . Primers were: EP2R-forward, 5Ј-caaacatttaagctgtggtcaagg-3Ј; EP2R-reverse, 5Ј-caaaaccacatactttgtcattcaa-3Ј; EP4R-forward, 5Ј-ccatgtcaggccactctcgc-3Ј; EP4R-reverse, 5Ј-ccagcctcatccaccagtaag-3Ј; A 2A R-forward, 5Ј-cttgggttctg aggaagcag-3Ј; A 2A R-reverse, 5Ј-cagcagctcctgaaccctag-3Ј; A 2B R-forward, 5Ј-gacacggctggttttcattg-3Ј; A 2B R-reverse, 5Ј-gctgttggcataatccacac-3Ј; EP1R-forward, 5Ј-accagatcctgg acccttg-3Ј, EP1R-reverse, 5Ј-tagaagtggctgaggccg-3Ј; EP3R-forward, 5Ј-agcccacccccaaatataac-3Ј, EP3R-reverse, 5Ј-tgc tccttgtcatgatgagtg-3Ј. Relative quantitative expression of those receptors was calculated by the comparative cycle cross-threshold method. DiVerences in gene expression were calculated using the C t method according to the manual from SA Bioscience.
Analysis of 3Ј, 5Ј-cAMP (cAMP) cAMP levels were measured by high-performance liquid chromatography-tandem mass spectrometry using a triple quadrupole mass spectrometer (TSQ Quantum-Ultra, ThermoFisher ScientiWc, San Jose, CA, USA) operating in the selected reaction monitoring mode with a heated electrospray ionization source as previously described [17, 22] .
Statistics
Statistical analyses were performed with t tests using the GraphPad PRISM software program. All data were expressed as mean § SD. The signiWcance level was set at p < 0.05. All experiments were repeated 2-5 times and representative data are presented.
Results
Inhibitory eVects of PGE 2 and CADO on the cytotoxic activity of TILs
The cytotoxic activity of anti-melanoma-speciWc TILs #2009 was tested against T2 cells pulsed with MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide in the absence or presence of PGE 2 or 2-chloroadenosine (CADO), a stable analog of adenosine that is resistant to metabolism by adenosine deaminase. PGE 2 or CADO substantially inhibited the cytotoxic activity of TILs, and in combination their inhibitory eVects were more profound compared with each agent used individually (Fig. 1a) . Treatment of target cells with CADO and/or PGE 2 did not increase 51 Cr release or aVect their sensitivity to TIL-mediated cytotoxicity. CADO and PGE 2 at the concentrations employed did not reduce the viability of TILs.
CGS (selective A 2A R agonist) or butaprost (selective EP2R agonist) also inhibited the cytotoxic activity of TILs (Fig. 1a) . In combination, CGS and butaprost showed substantially higher inhibitory eVects than each agent used alone, indicating that this increase was mediated via ampliWcation of A 2A R and EP2R inhibitory signaling. In contrast, the immunosuppressive factors TGF-and IL-10 at 10, 30 and 100 (not shown) ng/ml and even at 300 ng/ml did not inhibit the cytolytic activity of TILs (Fig. 1a) . These data indicate that adenosine and PGE 2 have a unique ability to inhibit the cytolytic function of TILs via A 2A R and EP2R signaling, respectively. TILs #2009 were also highly cytotoxic against HLA A2 + UPCI-MEL-136 melanoma cells, and in the presence of CGS (25-100 M), the cytotoxic activity of TILs was inhibited in a concentration-dependent manner. In combination, CGS and butaprost showed a substantially higher inhibitory eVect than each agent used separately (Fig. 1b) . PGE 2 and butaprost manifested more potent suppressive eVects and were able to inhibit the cytotoxic activity of TILs at lower concentrations than CADO and CGS. These potency diVerences were likely due to diVerences in expression of EP2Rs and A 2A Rs. Because the density of adenosine and PGE 2 receptors was too low for detection by Xow cytometry, we used real-time PCR to approximate the relative expression of these receptors. TILs expressed low levels of EP1R mRNA, whereas expression of EP2R mRNA was 92-fold higher. EP2R mRNA expression was 3.3-fold higher than EP4R mRNA expression (Fig. 1c) . TILs did not express A 1 R or A 3 R mRNA, expressed very low levels of A 2B R mRNA and expressed slightly higher levels of A 2A R mRNA. EP2R mRNA expression in TILs was 11.7-fold higher than A 2A R mRNA expression (Fig. 1d) . Low receptor density requires higher concentrations of ligands to trigger signaling. Indeed, in T cells of mice with only one A 2A R allele, concentrations of ligand must be substantially increased to provide suYcient signaling and induce cAMP production [23] .
Tumor-inWltrating lymphocytes from diVerent melanoma patients showed wide-ranging cytotoxic activity that varied from 20 to 90%. TILs also diVered in their sensitivity to the inhibitory eVects of CADO and PGE 2 . Some TILs were highly sensitive, whereas others showed only slight, if any, changes in their cytotoxicity in the presence of CADO and PGE 2 . We initially attributed these diVerences to the properties of individual TIL cell lines. Later, it became apparent that the same TILs tested at diVerent time periods in culture varied in their cytotoxic activity and sensitivity to CADO and PGE 2 that could be attributed to diVerences in their stage of diVerentiation during their ex vivo expansion. In total, we analyzed the cytotoxic activity of nine individual TIL lines. Five TIL lines had limited proliferative ability, and consequently supplies of these were exhausted during testing. Four TIL lines (#2009, #2044, #3072 and #2113) were highly proliferative and their cytotoxic activity and sensitivity to CGS and butaprost were analyzed at diVerent time periods in culture (Fig. 2) . Initially, these TIL lines showed high cytotoxic activity and resistance to the inhibitory eVects of CGS or butaprost, even in combination (Fig. 2 , stage I). After 3-4 weeks in culture, TILs exhibited reduced proliferation, yet still were highly cytotoxic but became sensitive to CGS and butaprost, that in combination manifested a remarkable inhibitory eVect (Fig. 2 , stage II). After an additional 1-2 weeks in culture, TILs showed a substantial reduction in their proliferation and cytotoxic activity but maintained high sensitivity to CGS and butaprost (Fig. 2, stage III) .
We considered that these changes represented three distinct stages of TIL diVerentiation and classiWed TILs into stages I and II when their cytotoxic activity was above 50% (at an E:T ratio 5:1) and below 50% at stage III. TILs at Our data indicate that in vitro expansion of TILs increases their sensitivity to the suppressive eVects of adenosine and PGE 2 and decreases their cytotoxic activity, which could reduce their eYcacy as adoptively transferred TILs in a tumor environment enriched with adenosine and PGE 2 . Therefore, it is important to develop an approach that could preserve or restore TIL cytotoxic activity and maintain their resistance to adenosine and PGE 2 . Based on the Wndings that ligand binding to A 2A Rs and EP2Rs causes receptor desensitization and internalization [24] [25] [26] , we hypothesized that desensitization of A 2A Rs and EP2Rs could block the suppressive eVects of PGE 2 and adenosine on the cytotoxic activity of TILs. To test this possibility, TILs #2679 or TILs #2009 were pretreated with CADO (5 M) and/or PGE 2 (5-25 nM) at concentrations that did not suppress TIL cytotoxicity. After overnight incubation, TILs were washed and the ability of CGS or butaprost to aVect the cytotoxic activity of non-pretreated or pretreated TILs was tested. CGS at 50 M and butaprost at 5 M substantially inhibited the cytotoxic activity of control, non-pretreated TILs #2679, and in combination they had higher suppressive eVects and reduced the cytotoxicity from 59 to 18.4% (Table 1) . Importantly, pretreatment with CADO or PGE 2 substantially increased the cytotoxic activity of TILs #2679 from 59 to 78.6%. Moreover, pretreated TILs #2679 became resistant to the inhibitory eVects of CGS and butaprost. In combination, CGS and butaprost only slightly inhibited TIL cytotoxic activity and actually their residual cytotoxicity was almost threefold higher than non-pretreated control TILs #2679 (Table 1) . Interestingly, TILs #2679 pretreated with PGE 2 were resistant to inhibitory signaling by both butaprost, an agonist of EP2Rs, as well as by CGS, an agonist of A 2A Rs. Likewise, pretreatment with CADO rendered TILs resistant to CGS as well as butaprost ( Table 1) . Retesting of TILs #2679 after 5 days in culture with IL-2 showed that their cytotoxic activity was reduced by twofold, signifying that TILs #2679 had entered stage III. They retained high sensitivity to the suppressive eVects of CADO and PGE 2 that in combination almost completely inhibited TIL cytotoxicity (Table 1) . Pretreatment with CADO or PGE 2 increased cytotoxic activity of TILs #2679 at stage III and induced cross-resistance to the suppressive eVects of butaprost and CGS ( Table 1) .
The experiments were repeated with TILs #2009 and similar results were obtained. TILs #2009 were highly cytotoxic but their activity was substantially reduced by CGS and butaprost, and in combination they reduced TIL cytotoxicity from 80.9 to 24.0%, indicating that these TILs were at stage II (Table 1) . After 10 days in culture, their cytotoxicity was reduced from 80.9 to 34% and they were highly sensitive to the inhibitory eVects of CGS and butaprost (Table 1) . Pretreatment of TILs #2009 at stage II or III with CADO or PGE 2 increased their cytotoxic activity and their resistance to the inhibitory eVects of CGS and butaprost. However, pretreatment of TILs with a combination of CADO and PGE 2 was not superior when compared with each modality used individually (Table 1) . These eVects were likely mediated via cAMP-elevating receptors because pretreatment of TILs with a speciWc agonist of EP2Rs, butaprost (1-2 M), had the same eVects as pretreatment with PGE 2 . Pretreatment of TILs with CGS (5-10 M) had similar but less eYcient eVects than butaprost. In general, PGE 2 was more eYcient than CADO with regard to stimulating TIL cytotoxicity and inducing resistance ( Table 1) .
Mechanism of resistance and sensitivity to the suppressive eVects of EP2R and A 2A R agonists
Tumor-inWltrating lymphocytes resistance to the inhibitory eVects of EP2R and A 2A R agonists at stage I could be due to ineYcient receptor signaling to produce cAMP or to high activity of phosphodiesterases (PDEs) that hydrolyze cAMP. In this regard, PDE4 is a major PDE form in T lymphocytes [27] . Therefore, if PDE4, by metabolizing cAMP induced by EP2R and A 2A R agonists, restricts their inhibitory eVects, rolipram, a speciWc inhibitor of PDE4, should increase intracellular concentrations of cAMP and inhibit the cytotoxic activity of TILs. In contrast to this prediction, rolipram alone did not inhibit the cytotoxic activity of TILs, and in combination with CADO and/or PGE 2 , rolipram only marginal inhibited cytotoxic activity of TILs (Fig. 3a) . These Wndings suggest that resistance of TILs is not solely based on high activity of PDE4. Next, we tested whether high concentrations of the A 2A R agonist CGS could overcome the resistance of TILs. CGS, even at 100 M, failed to inhibit TIL cytotoxicity. When CGS was used in combination with butaprost (5 M) a slight but signiWcant (p < 0.05) inhibition of TIL cytotoxicity was observed (Fig. 3b) . Similar levels of inhibition were found when either CGS or butaprost were used in combination with rolipram, an inhibitor of PDE4. Further inhibition of TIL cytotoxicity was achieved only when all three agents were combined (Fig. 3b) .
The resistance of TILs to EP2 and A 2A agonists could be due to insuYciency of receptor-mediated signaling and activation of adenylyl cyclase. If so, receptor-independent Table 1 EVects of CADO or PGE 2 pretreatment on TIL cytotoxic activity and sensitivity to the suppressive eVects of A 2A and EP2 receptor signaling a TILs #2679 or #2009 were pretreated overnight with CADO and/or PGE 2 or butaprost at the indicated concentrations. After washing, the cytotoxic activity of pretreated TILs was tested in the 4-h direct stimulation of adenylyl cyclase by forskolin should cause a substantial inhibition of TIL cytotoxicity. In contrast to this expectation, forskolin at 25 and 50 M failed to inhibit TIL cytotoxic activity. Even a very high concentration (100 M) forskolin caused only a slight inhibition (Fig. 3a) . In contrast, when TILs #2009 were tested at stage II they showed high sensitivity to the inhibitory eVects of forskolin. In this case, foskolin at 25 and 50 M reduced their cytotoxicity from 70.9 to 24.4% and 4.1%, respectively. Moreover, 100 M of forskolin completely inhibited TIL cytotoxicity at stage II (Fig. 3c) . It is possible that adenylyl cyclase of TILs at stage I fails to respond to A 2A R and EP2R signaling and to produce cAMP. However, TILs #2009 at stage I treated with CADO or PGE 2 were able to produce cAMP that was higher when combined treatment was applied (Fig. 3d) . The PDE4 inhibitor rolipram further increased levels of cAMP induced by CADO and/or PGE 2 (Fig. 3d) . Although CGS at 100 M failed to inhibit TIL cytotoxic activity (Fig. 3b) , this same concentration of CGS induced very high levels of cAMP in the same TILs. cAMP production further increased when CGS was used in combination with butaprost (Fig. 3e) .
Similarly, cAMP production was observed when TILs #2009 at stage II were treated with CADO or PGE 2 as well as CGS or butaprost, and in combination they induced much higher levels of cAMP (Fig. 4a) . In general, no diVerences in cAMP induction were observed between TILs at stages I and II, but TILs at stage II were sensitive to the immunosuppressive eVects of the agonists. These data support the concept that the resistance of stage I TILs to adenosine and PGE 2 is not due to ineYciencies in EP2R or A 2A R signaling and cAMP production or cAMP metabolism by PDE4 but rather to changes in signaling downstream of cAMP.
We next analyzed downstream mechanisms of cAMP signaling following treatment of stage II TILs with CADO or PGE 2 . Because cAMP activates PKA resulting in phosphorylation of CREB [14] , we examined whether treatment of TILs #2009 at stage II with CADO or PGE 2 triggers PKA activation and phosphorylation of CREB. Stimulation of TILs with anti-CD3 caused CREB phosphorylation, and 
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CADO or PGE 2 further increased the levels of CREB phosphorylation, and in combination they induced higher levels of CREB phosphorylation than each modality used alone (Fig. 4b ). These results demonstrate that the increased immunosuppressive eVects of adenosine and PGE 2 in combination are associated with ampliWcation of PKA activation. Because Csk is a downstream target of PKAI and is a physiological inhibitor of TCRs [28] [29] [30] [31] [32] , it is possible that CADO or PGE 2 induce Csk phosphorylation in TILs. Indeed, our western blot analysis showed that CADO or PGE 2 -induced phosphorylation of Csk that was more profound when CADO and PGE 2 were used in combination (Fig. 4c) .
Motivated by the fact that Csk regulates TCR signaling by inhibiting Lck [28] [29] [30] [31] [32] , we next analyzed Lck phosphorylation in TILs treated with CADO or PGE 2 . Lck can be phosphorylated on Y394 and Y505, leading to activation and inhibition of Lck, respectively [33] . In TILs, Lck was consistently phosphorylated on Y505. Treatment with CADO or PGE 2 further increased phosphorylation of the Lck Y505 inhibitory site, and this was more profound when combined treatment was applied (Fig. 5a) . Stimulation of TILs with anti-CD3-induced phosphorylation of Lck Y394 that was inhibited by CADO or PGE 2 (Fig. 5a) . Thus, CADO and PGE 2 increased Lck phosphorylation on inhibitory Y505 site, yet inhibited phosphorylation of the stimulatory Y394 site.
Using Xow cytometric analysis, we found that anti-CD3 stimulation induced phosphorylation of ZAP-70, and this response was inhibited by CADO and PGE 2 (Fig. 5b) . Because phosphorylation and activation of AKT is an important step in TCR-mediated activation and the cytotoxic activity of CTLs [34, 35] , it is conceivable that CADO and PGE 2 inhibit phosphorylation of Akt. In this regard, we observed that stimulation of TILs with anti-CD3-induced Akt phosphorylation that was substantially inhibited by CADO or PGE 2 (Fig. 5c) . Thus, it appears that the immunosuppressive eVects of CADO and PGE 2 in TILs are mediated via A 2A Rs and EP2Rs, which trigger a common pathway: elevated cAMP ! activation of PKA ! activation of Csk ! inhibition of Lck ! inhibition of ZAP-70 and TCR signaling.
Discussion
Although several studies clearly document the ability of PGE 2 to suppress inXammatory cytokine production by various immune cells [10, 12, 13, 21, 22] , our study for the Wrst time demonstrates that PGE 2 inhibits the cytolytic activity of human tumor-speciWc CTLs. CADO, a stable analog of adenosine has similar eVects, whereas other tested immunosuppressive factors, such as TGF-and IL-10, fail to directly inhibit the cytolytic function of TILs. In combination, CADO and PGE 2 have additive suppressive eVects.
Although the ability of PGE 2 to inhibit the cytolytic function of CTLs was not demonstrated the inhibitory eVect of adenosine was extensively investigated showing that adenosine attenuates the cytotoxic activity of allospeciWc murine CTLs via inhibiting the exocytosis of cytotoxic granules and by reducing FasL expression [13, 36, 37] . Our analysis of the mechanisms of immunosuppressive signaling indicates that adenosine and PGE 2 by binding to A 2A Rs and EP2Rs trigger cAMP production, leading to activation of PKA and CREB phosphorylation that is higher when these agents are used in combination. Our previous studies show that activation of PKA type I (PKAI), but not of PKA type II, mimics the inhibitory eVect of CADO on cytotoxic activity and cytokine production by human melanomaspeciWc CTLs. The importance of PKAI activation in the inhibitory signaling is further supported by Wnding that Rp-8-BrAMPS, a speciWc inhibitor of PKA type I, blocks this inhibitory eVect [22] . PKAI phosphorylates and activates Csk, a well-known physiological inhibitor of TCR signaling [29] . Csk is anchored by Cbp/PAG to lipid rafts and constitutively inhibits Lck and Fyn. Activation of TCR leads to dissociation of Csk from Cbp/PAG and releases Csk from lipid rafts thus allowing TCR signaling [28-32, 38, 39] . Our current studies show that treatment of human TILs with CADO or PGE 2 results in Csk phosporylation that is more profound when these agents are applied in combination. Csk phosphorylation is associated with inhibition of Lck, ZAP-70 and Akt phosphorylation. These results support the hypothesis that adenosine and PGE 2 trigger a common pathway involving PKA activation followed by Csk activation leading to inhibition TCR signaling. Combined CADO and PGE 2 treatment of TILs results in the ampliWcation of this inhibitory pathway signaling and increases its immunosuppressive eVects.
Adoptive immunotherapy necessitates isolation of small numbers of immune T lymphocytes from resected melanomas and their expansion to approximately 10 11 cells, which requires an extended period of in vitro simulation with IL-2. Our studies demonstrate that prolonged TIL stimulation with IL-2 exhausts their ability to proliferate, renders them sensitive to the inhibitory eVects of PGE 2 and adenosine and reduces their cytolytic activity. Based on these changes we identify three major transitional stages of TIL diVerentiation during their ex vivo expansion. Previous studies characterize stages of TIL diVerentiation during their culture with IL-2 based on their ability to proliferate and express PD-1, CD27 and its ligand CD70 [3, 40, 41] . However, we do not Wnd an association between changes in CD27/CD70 expression and TIL resistance/sensitivity to CADO and PGE 2 (data not shown).
Tumors contain elevated levels of PGE 2 and adenosine [18] [19] [20] . However, precise intratumor concentrations of adenosine are diYcult to determine due to adenosine's rapid hydrolysis by adenosine deaminase. An important issue is whether in vivo concentrations of adenosine are suYciently high to exert suppressive eVects. Findings that pharmacological blockade of A 2A Rs and genetic knockout of A 2A Rs substantially increase the eYcacy of antitumor T cell-mediated immunity in mice indicates that in vivo con- centrations of adenosine are suYciently immunosuppressive [20] . Taking into consideration the elevated intratumor levels of adenosine and PGE 2 and their highly suppressive activity, it is of great importance to develop an approach to increase resistance of TILs to the suppressive eVects of these factors. The immunosuppressive eVects of CADO and PGE 2 can be blocked by speciWc antagonists of A 2A Rs and EP2Rs [11, 17, 42] or by blocking PKAI activation with a speciWc inhibitor Rp-8-BrAMPS [17, 22, 38] . Also, treatment of murine allospeciWc CTLs with NECA, an agonist of A 2A Rs, for 2 days renders them resistant to the suppressive eVects of NECA that was attributed to selection of CTL variants with lower levels of A 2A Rs [43] .
We Wnd that overnight pretreatment of TILs at stages II and III with non-suppressive concentrations of CADO or PGE 2 increases TIL cytotoxic activity and their resistance to inhibitory signaling mediated via A 2A Rs and EP2Rs. These agents induce cross-resistance such that pretreatment with PGE 2 induces TIL resistance to inhibition by agonists of either EP2Rs (butaprost) or A 2A Rs (CGS). Similar eVects are induced by pretreatment with CADO. These eVects are probably mediated via desensitization and internalization of the inhibitory receptors. Due to the low density of adenosine and PGE2 receptors and to the lack of appropriate antibodies that recognize ligand bound and unbound receptors, Xow cytometric analysis or immunoXuorescence microscopy is not applicable for testing expression and internalization of these receptors. However, the mechanisms of desensitization and internalization of GPCRs, including adenosine and PGE 2 receptors, can be investigated using Wbroblast or malignant cells overexpressing these receptors following transfection with a plasmid encoding the HA-epitope tagged receptors. Indeed, internalization of receptors was then determined by loss of cell-surface immunoreactivity of HA-tagged receptors [24] [25] [26] . Such studies show that phosphorylation of serine and/ or threonine residues in the third intracellular loop and C terminus of receptors leads to homologous or heterologous desensitization. Homologous desensitization is speciWc for agonist-occupied receptors that are phosphorylated by one of the GPCR kinases (GRKs 1-7) . Heterologous desensitization is induced by cAMP activated PKA leading to phosphorylation of receptors that are not necessarily occupied by ligand. Phosphorylated receptors bind -arrestin that inhibits GPCR coupling and targets receptors to clathrincoated pits for internalization [24] [25] [26] . Thus, it is likely that the increased resistance of TILs to the immunosuppressive eVects of CADO and PGE 2 is due to internalization and desensitization of A 2A Rs and EP2Rs. Cross-resistance induced by TIL pretreatment with PGE 2 or CADO is likely based on their ability to activate PKA that leads to phosphorylation of A 2A Rs and EP2Rs and their internalization independent of the ligand binding.
It is of interest that pretreatment with CADO and PGE 2 stimulates TIL cytotoxicity, but the mechanisms of this stimulation are not clear. It is conceivable that pretreatment abolishes some controlling mechanisms. We consider that this pretreatment aVects some mechanisms controlling CTL activity. Accumulated evidence indicates that Csk is a physiological inhibitor of TCR signaling. It is possible that pretreatment of TILs with low concentrations of PGE2 or CADO provides low level of signaling triggering dissociation of Csk from Cbp/PAG anchoring complexes, releasing Csk from lipid rafts and liberating its inhibitory eVect on TCR and thus augmenting TIL cytotoxic activity.
Recent success in adoptive therapy of advanced melanoma is attributed to better understanding of conditions that provide prolonged survival of CTLs in the circulation [1, 2, 44] . Even so, transfused CTLs appear to lose their activity in the tumor microenvironment [3] [4] [5] [6] [7] . It is possible that this phenomenon is due to the presence of high intratumor concentrations of adenosine and PGE 2 . Thus, using TILs that have high cytotoxic activity and resistance to the suppressive eVects of adenosine and PGE 2 could be important for therapeutic eYcacy. Based on our Wnding that desensitization of A 2A R and EP2R increases TIL cytotoxic activity and their resistance to A 2A R and EP2R agonists, pretreatment of TILs with low concentrations of PGE 2 or butaprost before their adoptive transfer may be beneWcial and help to maintain therapeutic eYcacy of TILs even in the presence of high intratumor concentrations of adenosine and PGE 2 .
